Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

Abstract Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eva Serrano-Candelas, Rubén Martínez-Aranguren, Olga Vega, Gabriel Gastaminza, Joan Bartra, Maria Teresa Audicana, Jorge M. Núñez-Córdoba, Jaime Algorta, Antonio Valero, Margarita Martin, Marta Ferrer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/995bf92164984868a3e21c2d3ca0244e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:995bf92164984868a3e21c2d3ca0244e
record_format	dspace
spelling	oai:doaj.org-article:995bf92164984868a3e21c2d3ca0244e2021-12-02T15:05:20ZOmalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells10.1038/s41598-017-09361-42045-2322https://doaj.org/article/995bf92164984868a3e21c2d3ca0244e2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09361-4https://doaj.org/toc/2045-2322Abstract Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the in vivo administration of OmAb in a clinical trial. We found that OmAb added in vitro to sera from CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome maintained the capacity to activate mast cells and basophils. Thus, we conclude that the beneficial activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation.Eva Serrano-CandelasRubén Martínez-ArangurenOlga VegaGabriel GastaminzaJoan BartraMaria Teresa AudicanaJorge M. Núñez-CórdobaJaime AlgortaAntonio ValeroMargarita MartinMarta FerrerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Eva Serrano-Candelas Rubén Martínez-Aranguren Olga Vega Gabriel Gastaminza Joan Bartra Maria Teresa Audicana Jorge M. Núñez-Córdoba Jaime Algorta Antonio Valero Margarita Martin Marta Ferrer Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
description	Abstract Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb’s mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the in vivo administration of OmAb in a clinical trial. We found that OmAb added in vitro to sera from CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome maintained the capacity to activate mast cells and basophils. Thus, we conclude that the beneficial activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation.
format	article
author	Eva Serrano-Candelas Rubén Martínez-Aranguren Olga Vega Gabriel Gastaminza Joan Bartra Maria Teresa Audicana Jorge M. Núñez-Córdoba Jaime Algorta Antonio Valero Margarita Martin Marta Ferrer
author_facet	Eva Serrano-Candelas Rubén Martínez-Aranguren Olga Vega Gabriel Gastaminza Joan Bartra Maria Teresa Audicana Jorge M. Núñez-Córdoba Jaime Algorta Antonio Valero Margarita Martin Marta Ferrer
author_sort	Eva Serrano-Candelas
title	Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
title_short	Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
title_full	Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
title_fullStr	Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
title_full_unstemmed	Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
title_sort	omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/995bf92164984868a3e21c2d3ca0244e
work_keys_str_mv	AT evaserranocandelas omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT rubenmartinezaranguren omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT olgavega omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT gabrielgastaminza omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT joanbartra omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT mariateresaaudicana omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT jorgemnunezcordoba omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT jaimealgorta omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT antoniovalero omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT margaritamartin omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells AT martaferrer omalizumabefficacyincasesofchronicspontaneousurticariaisnotexplainedbytheinhibitionofseraactivityineffectorcells
_version_	1718388847945973760

Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

Ejemplares similares